Akeso's ivonescimab beats durvalumab in biliary tract cancer trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. META
9. AMC
10. ACN

Go back to Akeso's ivonescimab beats durvalumab in biliary tract cancer trial
Stratcomm Media, Ltd. (NASDAQ: SMMT) Delayed: 16.90 -0.95 (5.32%)
Previous Close $17.85    52 Week High $19.75 
Open $18.40    52 Week Low $4.26 
Day High $18.42    P/E N/A 
Day Low $16.64    EPS $0.00 
Volume 5,780,327